Select therapeutic use:
Indications for Hydralazine Injection:
Severe essential hypertension when oral therapy not feasible or there is an urgent need to lower blood pressure.
Monitor BP closely. 20–40mg; repeat as needed. Advanced renal damage: reduce dose.
Not recommended; doses of 1.7–3.5mg/kg per day in 4–6 divided doses have been used.
Coronary artery disease. Mitral valve disease.
Suspected coronary artery disease. Cerebrovascular accidents. Aortic aneurysm. Increased intracranial pressure. Renal disease. Treat paresthesias and/or numbness with pyridoxine. Discontinue if blood dyscrasias occur. Obtain CBC and ANA titer periodically; consider discontinuing if SLE occurs. Surgery. Pregnancy (Cat.C). Nursing mothers.
Caution with MAOIs. Profound hypotension with potent parenteral antihypertensives (eg, diazoxide). Antagonized by NSAIDs. May block epinephrine.
Headache, anorexia, GI disturbances, palpitations, edema, flushing, nasal congestion, lacrimation, rash, tachycardia, angina, orthostatic hypotension, blood dyscrasias, peripheral neuritis, SLE.
Formerly known under the brand names Apresoline (inj, tabs); Dralzine (tabs).